Research programme: siRNA cancer therapeutics - Quark Pharmaceuticals

Drug Profile

Research programme: siRNA cancer therapeutics - Quark Pharmaceuticals

Alternative Names: QP-EN1; QP-EN2

Latest Information Update: 17 Nov 2015

Price : $50

At a glance

  • Originator Quark Pharmaceuticals
  • Class Proteins
  • Mechanism of Action Hypoxia inducible factor 1 stimulants; NF-E2-related factor 2 inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer
  • Research Sarcoma

Most Recent Events

  • 17 Nov 2015 Early research in Sarcoma in USA (Parenteral)
  • 31 Aug 2010 Preclinical development is ongoing USA
  • 12 Oct 2008 Preclinical trials in Cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top